RY 174.39 2.4016% SHOP 149.115 2.5974% TD-PFM 24.63 -0.0811% TD-PFL 24.7 0.2028% TD 78.325 0.1214% ENB 60.6 1.3039% BN 80.4 1.9787% TRI 226.27 0.7525% CNQ 48.285 2.2771% CP 104.53 1.6038% CNR 151.74 1.5459% BMO 132.69 0.9203% BNS 78.845 0.1715% CSU 4600.2002 2.157% CM 91.15 0.474% MFC 45.79 1.6878% ATD 78.38 1.5285% NGT 60.14 0.0499% TRP 70.15 1.977% SU 57.44 0.5954%
Last update at 2024-11-20T20:00:00Z
Siemens Healthineers Third Quarter 2024 Earnings: Misses Expectations
Mon 19 Aug 24, 05:13 AM| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | 1928.00M | 2800.00M | 2404.00M | 1954.00M | 2193.00M |
| Minority interest | -16.00000M | -17.00000M | -18.00000M | 13.00M | 13.00M |
| Net income | 1509.00M | 2038.00M | 1727.00M | 1411.00M | 1567.00M |
| Selling general administrative | 3607.00M | 3408.00M | 2817.00M | 2279.00M | 2214.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 7709.00M | 8137.00M | 6952.00M | 5580.00M | 5796.00M |
| Reconciled depreciation | 1557.00M | 1343.00M | 1039.00M | 815.00M | 620.00M |
| Ebit | 2224.00M | 2918.00M | 2476.00M | 1996.00M | 2316.00M |
| Ebitda | 3781.00M | 4261.00M | 3515.00M | 2811.00M | 2936.00M |
| Depreciation and amortization | 1557.00M | 1343.00M | 1039.00M | 815.00M | 620.00M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 2224.00M | 2918.00M | 2476.00M | 1996.00M | 2316.00M |
| Other operating expenses | 19547.00M | 18790.00M | 15440.00M | 12516.00M | 12222.00M |
| Interest expense | 296.00M | 118.00M | 83.00M | 76.00M | 123.00M |
| Tax provision | 403.00M | 746.00M | 658.00M | 532.00M | 607.00M |
| Interest income | 85.00M | 48.00M | 33.00M | 53.00M | 38.00M |
| Net interest income | -207.00000M | -127.00000M | -170.00000M | -28.00000M | -107.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 403.00M | 746.00M | 658.00M | 532.00M | 607.00M |
| Total revenue | 21680.00M | 21714.00M | 17997.00M | 14460.00M | 14518.00M |
| Total operating expenses | 5576.00M | 5213.00M | 4395.00M | 3636.00M | 3500.00M |
| Cost of revenue | 13971.00M | 13577.00M | 11045.00M | 8880.00M | 8722.00M |
| Total other income expense net | -296.00000M | -118.00000M | -72.00000M | -42.00000M | -123.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1525.00M | 2054.00M | 1746.00M | 1422.00M | 1586.00M |
| Net income applicable to common shares | - | 2038.00M | 1727.00M | 1411.00M | 1567.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 46684.00M | 49056.00M | 42162.00M | 25094.00M | 21429.00M |
| Intangible assets | 7726.00M | 8712.00M | 8211.00M | 1912.00M | 1576.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 25.00M | 28.00M | 25.00M | 27.00M | 12.00M |
| Total liab | 28551.00M | 29204.00M | 25823.00M | 12583.00M | 11647.00M |
| Total stockholder equity | 18081.00M | 19836.00M | 16321.00M | 12498.00M | 9769.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 168.00M | 178.00M | 213.00M | 136.00M | 148.00M |
| Common stock | 1128.00M | 1128.00M | 1128.00M | 1075.00M | 1000.00M |
| Capital stock | 1128.00M | 1128.00M | 1128.00M | 1075.00M | 1000.00M |
| Retained earnings | 1381.00M | 894.00M | -300.00000M | -1276.00000M | -1859.00000M |
| Other liab | - | 3369.00M | 3594.00M | 1998.00M | 1951.00M |
| Good will | 18118.00M | 19061.00M | 17512.00M | 9038.00M | 8590.00M |
| Other assets | - | 4070.00M | 2141.00M | -1.00000M | 1429.00M |
| Cash | 1642.00M | 1436.00M | 1322.00M | 656.00M | 920.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 13440.00M | 12024.00M | 10065.00M | 7289.00M | 5605.00M |
| Current deferred revenue | 10872.00M | 9282.00M | 7682.00M | 5630.00M | 3974.00M |
| Net debt | -1009.00000M | -704.00000M | -569.00000M | -175.00000M | -779.00000M |
| Short term debt | 197.00M | 249.00M | 249.00M | 167.00M | 80.00M |
| Short long term debt | 31.00M | 67.00M | 73.00M | 60.00M | 70.00M |
| Short long term debt total | 633.00M | 732.00M | 753.00M | 481.00M | 141.00M |
| Other stockholder equity | 15572.00M | 17814.00M | 15493.00M | 12699.00M | 10628.00M |
| Property plant equipment | - | 3632.00M | 3295.00M | 2510.00M | 1944.00M |
| Total current assets | 14136.00M | 13379.00M | 10824.00M | 10268.00M | 7779.00M |
| Long term investments | - | - | - | - | 132.00M |
| Net tangible assets | - | -7937.00000M | -9493.00000M | 1548.00M | -397.00000M |
| Short term investments | 124.00M | 162.00M | 79.00M | 31.00M | 28.00M |
| Net receivables | 8084.00M | 7781.00M | 6244.00M | 7280.00M | 4773.00M |
| Long term debt | 10.00M | 15.00M | 19.00M | 49.00M | 39.00M |
| Inventory | 4261.00M | 3972.00M | 3154.00M | 2274.00M | 2046.00M |
| Accounts payable | 2203.00M | 2315.00M | 1921.00M | 1356.00M | 1403.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1924.00M | 2925.00M | 1244.00M | 580.00M | 600.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 32548.00M | 35677.00M | 31338.00M | 14827.00M | 13650.00M |
| Capital lease obligations | 592.00M | 650.00M | 590.00M | 372.00M | 32.00M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | -1069.00000M | 15.00M | 15.00M | -1.00000M | -1.00000M |
| Change to liabilities | - | 791.00M | 643.00M | 128.00M | 268.00M |
| Total cashflows from investing activities | - | -868.00000M | -14140.00000M | -1912.00000M | -647.00000M |
| Net borrowings | - | -169.00000M | -155.00000M | -101.00000M | 52.00M |
| Total cash from financing activities | -690.00000M | -1644.00000M | 11839.00M | -249.00000M | -603.00000M |
| Change to operating activities | - | -663.00000M | 453.00M | -39.00000M | -140.00000M |
| Net income | 1525.00M | 2054.00M | 1746.00M | 1423.00M | 1586.00M |
| Change in cash | 206.00M | 114.00M | 666.00M | -264.00000M | 401.00M |
| Begin period cash flow | 1436.00M | 1322.00M | 656.00M | 920.00M | 519.00M |
| End period cash flow | 1642.00M | 1436.00M | 1322.00M | 656.00M | 920.00M |
| Total cash from operating activities | 2119.00M | 2504.00M | 2933.00M | 1928.00M | 1617.00M |
| Issuance of capital stock | - | 1.00M | 2311.00M | 2709.00M | - |
| Depreciation | 1557.00M | 1343.00M | 1039.00M | 815.00M | 620.00M |
| Other cashflows from investing activities | - | - | 1.00M | 1.00M | 1.00M |
| Dividends paid | -1066.00000M | -955.00000M | -856.00000M | -798.00000M | 699.00M |
| Change to inventory | -453.00000M | -481.00000M | -22.00000M | -332.00000M | -124.00000M |
| Change to account receivables | - | -478.00000M | -720.00000M | 55.00M | -485.00000M |
| Sale purchase of stock | -421.00000M | -309.00000M | -255.00000M | -67.00000M | -51.00000M |
| Other cashflows from financing activities | 1354.00M | -232.00000M | 10777.00M | -1853.00000M | 147.00M |
| Change to netincome | - | -46.00000M | -187.00000M | -110.00000M | -89.00000M |
| Capital expenditures | 838.00M | 852.00M | 674.00M | 557.00M | 579.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -602.00000M | -831.00000M | 354.00M | -188.00000M | -481.00000M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -361.00000M | -62.00000M | -206.00000M | -122.00000M | -108.00000M |
| Free cash flow | 1281.00M | 1652.00M | 2259.00M | 1371.00M | 1038.00M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SEMHF Siemens Healthineers AG |
- -% | 51.20 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
| ABT Abbott Laboratories |
1.33 1.15% | 117.26 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
4.08 1.06% | 389.76 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
0.62 0.74% | 84.73 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
1.38 1.53% | 91.55 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. It operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. Its Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, solutions, and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services, and digital solutions and applications for managing treatment and therapy. Its Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms. It offers essential technical customer service, such as maintenance and repair; medical equipment performance management training; clinical education and e-learning; planning and design; financing; asset management; and managed departmental services for laboratories and healthcare facilities, as well as digital healthcare consulting, products, and services. The company is headquartered in Forchheim, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
Henkestrasse 127, Erlangen, Germany, 91052
| Name | Title | Year Born |
|---|---|---|
| Dr. Bernhard Montag | Pres, CEO & Chairman of Management Board | 1969 |
| Dr. Jochen Schmitz | CFO & Member of Management Board | 1966 |
| Ms. Darleen Caron | Chief HR Officer, Labor Director & Member of Management Board | 1964 |
| Ms. Elisabeth Staudinger | Member of Management Board | 1970 |
| Mr. Marc Koebernick | Head of Investor Relations | NA |
| Dr. Michel Therin D.V.M., Ph.D. | Pres of Advanced Therapies | 1961 |
| Christian Klaussner | Exec. VP of Fin. | NA |
| Andre Hartung | Head of Imaging | NA |
| Mr. Christopher A. Toth | Head of Varian | 1979 |
| Carsten Bertram | Head of Advanced Therapies | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...